Pfizer gets unexpected boost from Covid vaccine and pill
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to fend off criticism from an activist investor that has argued the company squandered its pandemic gains and needs a new path forward.
Pfizer shares, which had risen Tuesday morning after improved demand for the Covid vaccine, dropped 2.3% after Kennedy's ...
After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely ...
Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...
We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Pfizer Inc. (NYSE:PFE), one of the world's largest pharmaceutical companies with a market capitalization of $151.25 billion, finds itself at a critical juncture as it navigates the post-pandemic ...
Idaho Sen. Brandon Shippy proposes bill to ban mRNA vaccines until 2035 by incorrectly categorizing them as gene therapy, ...
Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...
It’s been almost four years since the U.S. Food and Drug Administration approved the first Covid-19 vaccine. Emphasis has been given to get the jab as it can help to protect you against developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback